CliffBio
small molecule

KEPPRA XR

LEVETIRACETAM

Loss of exclusivitySeptember 2028latest FDA-listed patent expiry
CompanyUCB →View the full company profile on CliffBio

Drug detail

Brand nameKEPPRA XR
Active ingredientLEVETIRACETAM
Strength500MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2008
Marketing statusRX

Listed patents

PatentExpiresType
7858122September 2028product

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KEPPRA XR patent cliff — loss of exclusivity September 2028 | CliffBio